{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05723107",
            "orgStudyIdInfo": {
                "id": "22-00249"
            },
            "organization": {
                "fullName": "NYU Langone Health",
                "class": "OTHER"
            },
            "briefTitle": "EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)",
            "officialTitle": "Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "eus-rfa-for-treatment-of-pancreatic-ductal-adenocarcinoma-pdac"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-01",
            "studyFirstSubmitQcDate": "2023-02-09",
            "studyFirstPostDateStruct": {
                "date": "2023-02-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NYU Langone Health",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Taewoong Medical",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Chemotherapy plus EUS-RFA",
                    "type": "EXPERIMENTAL",
                    "description": "Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer.\n\nStudy participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing.\n\nChemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15).",
                    "interventionNames": [
                        "Drug: Chemotherapy",
                        "Device: Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Chemotherapy",
                    "description": "Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.",
                    "armGroupLabels": [
                        "Chemotherapy plus EUS-RFA"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)",
                    "description": "EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).\n\nThe device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes.",
                    "armGroupLabels": [
                        "Chemotherapy plus EUS-RFA"
                    ],
                    "otherNames": [
                        "EUSRA RF Electrode"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0",
                    "description": "Per Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0, Grade III AEs are defined as severe or medically significant but not immediately life-threatening; or hospitalization or prolongation of hospitalization indicated; or disabling; or limiting self care activities of daily living. Grade IV AEs are defined as life-threatening consequences; or urgent intervention indicated.",
                    "timeFrame": "Up to Week 15"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants who Complete all 3 EUS-RFA Treatments",
                    "description": "Treatments delivered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11).",
                    "timeFrame": "Up to Week 11"
                },
                {
                    "measure": "Disease-Free Survival from Diagnosis",
                    "description": "Time from diagnosis to first clinical evidence of local or distant recurrence.",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Disease-Free Survival from First Study Procedure",
                    "description": "Time from first study procedure (delivered during Weeks 1-3) to first clinical evidence of local or distant recurrence.",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Overall Survival From Diagnosis",
                    "description": "Time from diagnosis to death.",
                    "timeFrame": "Up to Week 24"
                },
                {
                    "measure": "Percentage of Participants who Report Post-Procedural Complications",
                    "timeFrame": "Up to Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed and histologically confirmed PDAC by biopsy\n* Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter\n* ECOG performance status 0-2\n* Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis\n* Lesions between 1 - 4cm in size\n\nExclusion Criteria:\n\n* Patients that show evidence of distant metastasis\n* Endoscopically non-accessible mass\n* Pregnant patients\n* Inability to provide informed consent\n* Lesions \\<1cm, or \\>4cm in greatest diameter",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tamas A. Gonda, MD",
                    "role": "CONTACT",
                    "phone": "212-263-3095",
                    "email": "Tamas.Gonda@nyulangone.org"
                },
                {
                    "name": "Emil Agarunov",
                    "role": "CONTACT",
                    "phone": "212-263-3095",
                    "email": "Emil.agarunov@nyulangone.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Tamas A. Gonda, MD",
                    "affiliation": "NYU Langone Health",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Tisch Hospital",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tamas A. Gonda, MD",
                            "role": "CONTACT",
                            "phone": "212-263-3095",
                            "email": "Tamas.Gonda@nyulangone.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: \\[Tamas.Gonda@nyulangone.org\\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.",
            "accessCriteria": "The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Tamas.Gonda@nyulangone.org. To gain access, data requestors will need to sign a data access agreement."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}